Lewis Zhang

Opinion author

Lewis Zhang is a healthcare investment banking professional with experience across U.S. and Asian markets. His work and independent research focus on biotech financing, licensing and strategic transactions. He currently works at a global investment bank and previously held healthcare investment banking roles at CLSA and Citi Orient Securities. He holds an MBA from Columbia Business School. The views expressed are his own.

Businessman Jumping from Broken Ladder to New Ladder of Success

Opinion

How Abogen went from COVID hype to a $7.8B Novartis deal

After Abogen Biosciences’ COVID shot missed the commercial window, the big question was whether its mRNA technology could create value beyond vaccines. Novartis’ $575 million upfront commitment is the clearest external validation yet of that broader therapeutic potential.

October 9, 2026

5 min read

Lewis Zhang